maintenance 10, 19, 20 . Critical questions remain as to how the epigenetic modifiers integrate multiple pathways to ensure that the appropriate amount of myelin is wrapped around axons during myelination and remyelination after injury. As many of the epigenetic modifiers act as repressors of gene expression, we hypothesized that deficient or limited SC remyelination after injury or pathological insult is caused by epigenetic silencing of the regulators required for myelinogenesis and myelin regeneration.
RESULTS
Identification of HDAC3 as an inhibitor of SC myelination by epigenetic screening EGR2 is a promyelinating regulator that serves as an indicator of myelinogenic potential. We developed an unbiased gene-expression-based assay using real-time qPCR indexing of Egr2 to identify inhibitors of epigenetic enzymes that blocked SC maturation. Cultured rat SCs were treated with a library of epigenetic compounds targeting these enzymes, including methyltransferases, demethylases, histone acetyltransferases, histone deacetylases (HDACs), and acetylated lysinereader proteins. We identified a set of compounds that enhanced Egr2 expression over vehicle treatment by fivefold or more ( Fig. 1a and Supplementary Fig. 1 ). Among these lead compounds were three inhibitors that preferentially targeted HDAC3: pimelic diphenylamide 106 (PDA106), RGFP966, and apicidin 21, 22 . The convergent effects of chemically dissimilar compounds suggest that effects were exerted through HDAC3 inhibition.
To investigate the effects of HDAC inhibition on SC maturation, we treated SCs isolated from neonatal rat sciatic nerve with inhibitors of HDAC1 and 2 (HDAC1/2; FK228), HDAC8 (PCI34051), and HDAC3 (RGFP966 and PDA106). Treatment with the HDAC1/2 inhibitor reduced extension of SC processes and expression of the mature SC markers myelin protein zero (MPZ) and peripheral myelin protein 22 (PMP22; Fig. 1b,c) , corroborating an essential role for HDAC1/2 in SC maturation 23, 24 . HDAC8 inhibition had a minimal effect on SC morphology (Fig. 1b) . In contrast, treatment with HDAC3 inhibitors resulted in an expansion of cellular processes; actin cytoskeleton augmentation, as shown by phalloidin staining; and induction of MPZ and PMP22 expression, as assessed by immunocytochemistry and qRT-PCR (Fig. 1b,c) , suggesting that inhibition of HDAC3 activity promotes the maturation process of SCs in vitro.
To evaluate the effects of HDAC3 inhibition in vivo, we administered RGFP966 or PDA106 via intraperitoneal (i.p.) injection into neonatal mice daily beginning at postnatal day (P) 1. Treatment continued until sciatic nerves were excised for analysis at P7 and P15. Both HDAC3 inhibitors caused an elevation in the number of EGR2-expressing mature SCs in sciatic nerves, consistent with our in vitro data (Fig. 1d,e) . Treatment also significantly elevated expression of myelinationassociated genes, including Prx, Mbp, Mpz, and Egr2, as compared to vehicle-treated control mice at P7 (Fig. 1f) . Ultrastructural analysis of sciatic nerves by electron microscopy (EM) revealed an increase in myelin thickness (assessed through analysis of g ratios, defined as the inner axon diameter divided by the outer diameter of the myelinated sheath; Fig. 1g-j) and the percentage of myelinated axons (Fig. 1k) in HDAC3-inhibitor-treated mice relative to controls at P7 and P15. Although treatment initiated at either P7 or P14 enhanced myelination, treatment starting at P7 produced a more profound enhancement of myelin thickness than that beginning at P14; however, the numbers of EGR2 + SCs in the groups were comparable at P24, indicating that growth of myelin sheath in SCs is more responsive to HDAC3 inhibitors at earlier developmental stages (Supplementary Fig. 2 ).
HDAC3 inhibition enhances SC remyelination and functional recovery after sciatic nerve transection
We next evaluated whether treatment with HDAC3 inhibitors after nerve injury would enhance remyelination and functional recovery of nerve conduction, which depends on the myelination state 5, 25 . We performed sciatic nerve transection of the right hindlimb in a group of 8-week-old adult mice and then treated these mice with an HDAC3 inhibitor, either RGFP966 or PDA106 at a dose that resulted in effective inhibition of HDAC3 activity without adverse effects daily over the first week and every 2 d during the second week for a total of 3 d 21, 26, 27 . After peripheral nerve transection in mice, denervated SCs resume proliferation, which is followed by differentiation and remyelination of regenerated axons 11 . We focused our analysis on the regenerating site, defined as a tissue bridge consisting of the SC-axon growth tip proximal to the injury 11, 12 . At 6 days post injury (d.p.i.), when SCs had extensively migrated into bridge tissue 5, 28 , the bridge appeared transparent despite considerable axonal regrowth in the vehicle-treated mice, suggesting that little myelin regeneration occurred spontaneously within this time period (Fig. 2a) . In contrast, opaque regeneration tracks were observed within the bridges of RGFP966-and PDA106-treated mice (Fig. 2a) , suggesting an accelerated regeneration of myelin sheath. The percentage of myelin basic protein (MBP) + myelinating axons entering the bridge of regenerating sciatic nerves was significantly higher in RGFP966-and in PDA106-treated mice than in vehicle-treated mice (Fig. 2b,c) . Following treatment with an HDAC3 inhibitor, the proportion of EGR2 + maturing SCs in the tissue bridge increased (Fig. 2d,e ) and the percentage of Ki67 + cells decreased, suggesting increased SC differentiation accompanied by reduced proliferation (Fig. 2d,e) . To further assess the extent of remyelination, we performed EM analysis on the regenerating sciatic nerves. At 14 d.p.i., both RGFP966-and PDA106-treated mice exhibited significantly thicker myelin sheaths in axons of different calibers in the regenerating bridge (Fig. 2f,g and Supplementary  Fig. 3a ) and an increased number of myelinated axons as compared to vehicle-treated mice (Fig. 2h) . Similarly, at 18 and 35 d.p.i., there was a significant increase in myelin thickness after HDAC3 inhibitor treatment relative to that following vehicle treatment (Fig. 2i,j and Supplementary Fig. 3b,c) .
To investigate whether the increase in remyelination after HDAC3 inhibition improved motor function in injured nerves, we measured in vivo conduction velocity and compound muscle action potentials (CMAPs) in injured sciatic nerves at different stages (18 and 35 d.p.i.) in adult mice treated with RGFP966 or PDA106 for 2 weeks (Fig. 2k) . At 18 d.p.i., CMAP activity was barely detectable after electrical stimulation of injured nerves in vehicle-treated mice. In contrast, an increase in conduction velocity and CMAP amplitude was observed in the injured nerves of inhibitor-treated mice (Fig. 2l,m) . At 35 d.p.i., electrophysiological recordings indicated weak CMAP activity in the injured nerves of vehicle-treated mice, whereas treatment with RGFP966 substantially improved motor function in nerves ( Supplementary Fig. 4) .
Furthermore, we found that short-term 10-d treatment of injured mice with an HDAC3 inhibitor starting at 1 d.p.i. enhanced recovery of both sensory and motor functions, as measured by response to pinprick stimulation ( Fig. 2n-p) and toe-spreading reflex (Fig. 2q,r) , respectively, at 24 d.p.i. This result was observed 3 months after treatment (94 d.p.i.; Fig. 2p,r) , when nerve function remained compromised in vehicletreated control mice; this is in keeping with the increased myelin thickness in HDAC3-inhibitor-treated mice at this stage ( Supplementary  Fig. 3d,e) . Moreover, the rotarod test confirmed functional improvement in motor performance after inhibitor treatment (Fig. 2s) . © 2018 Nature America, Inc., part of Springer Nature. All rights reserved. VOLUME 24 | NUMBER 3 | MARCH 2018 nAture medicine (2, 6) = 60.53, P veh versus RGFP966 = 0.0004, P veh versus PDA106 = 0.0001). (g) Representative electron micrographs of sciatic nerve cross-sections at P7 from mice treated with vehicle, RGFP966, or PDA106. n = 3 mice per group with 10 images for each mouse. Scale bars, 2 µm. (h) Quantification of g ratios for axons in sciatic nerves at P7 from mice treated with vehicle, RGFP966, or PDA106. n = 301 axons from 3 vehicle-treated mice, 300 axons from 3 RGFP966-treated mice, and 240 axons from 3 PDA106-treated mice; one-way ANOVA with Tukey's multiplecomparisons test (F (2, 838) = 213.9, P veh versus RGFP966 < 0.0001, P veh versus PDA106 < 0.0001). (i) Representative electron micrographs of sciatic nerve cross-sections taken at P15 from mice treated with vehicle, RGFP966, or PDA106. n = 3 mice per group with 10 images for each mouse. Scale bars, 2 µm. (j) Quantification of g ratios for axons in sciatic nerves at P15 from mice treated with vehicle, RGFP966, or PDA106. n = 300 axons from 3 mice for each group; one-way ANOVA with Tukey's multiple-comparisons test (F (2, 897) = 540.5, P veh versus RGFP966 < 0.0001, P veh versus PDA106 < 0.0001).
(k) The percentage of myelinated axons among total axons in sciatic nerves at P7 and P15 from mice treated with vehicle, RGFP966, or PDA106. Data are presented as mean ± s.e.m.; n = 6 mice per group; one-way ANOVA with Tukey's multiple-comparisons test (P7: F (2, 15) = 8.807, P veh versus RGFP966 = 0.0042, P veh versus PDA106 = 0.0111; P15: F (2, 15) = 6.541, P veh versus RGFP966 = 0.0136, P veh versus PDA106 = 0.0239). n.s., not significant; *P < 0.05, **P < 0.01, ***P < 0.001.
Myelin morphology was unaltered in uninjured intact nerves of the left hindlimb during the treatment period ( Supplementary Fig. 5 ), indicating that transient administration of an HDAC3 inhibitor did not elicit hypermyelination in uninjured nerves of adult mice at 2 months of age. There was an age-related decline in the level of HDAC3 expression in SCs of adult peripheral nerves as compared to developing peripheral nerves (Supplementary Fig. 6 ). Considering the ageassociated deficits in functional recovery after nerve injury in aged mice compared with young adult mice at 2 months of age 29 , we assessed the efficacy of HDAC3 inhibition in 10-to 12-month-old mice and found that this treatment enhanced nerve conductivity after sciatic nerve transection (Supplementary Fig. 7 ). These data show that pharmacological attenuation of HDAC3 activity after sciatic nerve transection accelerates SC remyelination and improves functional recovery.
Ablation of Hdac3 in SCs leads to hypermyelination in sciatic nerves
To determine whether the effect of HDAC3 inhibitors in promoting myelination is intrinsic to SCs, we transfected rat SC cultures with an siRNA designed to silence Hdac3 expression (siHdac3; Fig. 3a) . Hdac3 silencing resulted in increased amounts of the myelin proteins MBP and MPZ (Fig. 3a) . To assess the myelination capacity of SCs, we performed an SC-neuron co-culture assay in which primary rat SCs (SOX10 + ) treated with or without siHdac3 were seeded onto dorsal root ganglion (DRG) cultures 30 . After 10 d of culture in promyelinating medium containing 50 µg/ml ascorbic acid, the extent of myelination, as determined through immunolabeling for MBP, was substantially greater in Hdac3-deficient SC cultures than the control-transfected SCs (Fig. 3b) . Further, the number of myelinated segments was increased by approximately fourfold in Hdac3-deficient SC cultures relative to controls (Fig. 3c) .
To assess the cell-intrinsic role for HDAC3 in SC myelination in vivo, we generated mice lacking Hdac3 in SCs by crossing mice in which Hdac3 was flanked by loxP sites (floxed; Hdac3 fl/fl ) 31 with a mouse line in which cells of SC lineage expressed Cre recombinase under the control of the 2′,3′-cyclic nucleotide 3′ phosphodiesterase (Cnp) promoter (Cnp-Cre) 32 (Fig. 3d) . HDAC3 expression was lower in the sciatic nerves of Hdac3 fl/fl ; Cnp-Cre +/− (referred to here as Hdac3-cKO) mice than in controls ( Fig. 3d and Supplementary  Fig. 8 ). Hdac3 +/fl ; Cnp-Cre +/− or Hdac3 fl/fl littermates were phenotypically normal during SC development and were used as controls.
The number of SOX10-expressing cells of SC lineage was comparable between the sciatic nerves of control mice and Hdac3-cKO mutants, and the proportion of differentiated EGR2 + SCs was higher in Hdac3-cKO mutants than in controls at P7 (Supplementary Fig. 9 ). Ultrastructural analysis of sciatic nerves from Hdac3-cKO neonates at P1 showed an increase in myelinated axons relative to controls, indicating an accelerated onset of myelination in the absence of Hdac3 (Fig. 3e,f) . By P7, an active phase of myelinogenesis, Hdac3-cKO axons were hypermyelinated, with significantly more layers of myelin lamellae than observed in controls (Fig. 3g,h ). At P12, the formation of localized myelin protrusions or outfoldings appeared in hypermyelinated fibers (Fig. 3i) . At P18, massive myelin lamellar wrapping was observed in toluidine blue-stained semithin sections and EM graphs of cross-sections ( Fig. 3j ) and longitudinal sections ( Supplementary  Fig. 10a ) from sciatic nerves of Hdac3-cKO mice; this wrapping eventually led to demyelination in adulthood (Supplementary Fig. 10b ). Similar phenotypes were also detected in another mouse line with Hdac3 deletion, in which cells of SC lineage expressed Cre recombinase under the control of the desert hedgehog (Dhh) promoter (Hdac3 fl/fl ; DhhCre +/− (referred to as Hdac3-cKO Dhh ) 33 ; Supplementary Fig. 11 ).
To exclude effects of Hdac3 deletion on embryonic SC development, we inactivated Hdac3 in postnatal SCs in a mouse line with expression of tamoxifen-inducible Cre recombinase driven by the proteolipid protein (myelin) 1 (Plp1) promoter (Plp1-Cre ERT ) 34 through tamoxifen administration from P0 to P10 (Fig. 3k) . At P15, Hdac3 fl/fl ; Plp1-Cre ERT (referred to as Hdac3-iKO) mice exhibited hypermyelination in sciatic nerves as compared to controls (Fig. 3k,l) .
To further examine effects of Hdac3 deletion on premyelinating SCs, we ablated Hdac3 through treating Hdac3-iKO mice with tamoxifen from P6 to P34 (Fig. 3m) and excised their sciatic nerves at P108. The redundant myelin sheaths in SCs from tamoxifen-treated Hdac3-iKO mice were dramatically thicker than in controls, to the point of causing axonal resection (Fig. 3m,n) . Ablation of Hdac3 induced at the early postnatal stage P11 exerted a more robust effect on the enhancement of myelin thickness than ablation at P30 ( Supplementary  Fig. 12 ). In contrast, tamoxifen administration after mice had reached adulthood did not alter myelin morphology substantially, despite a modest increase of myelin thickness in axons with a small diameter ( Supplementary Fig. 13 ); this result is consistent with the low expression levels of HDAC3 in adult nerves.
Hdac3 deletion enhances SC remyelination and myelin thickness after injury
To test whether the effect of HDAC3 inhibitors on remyelination was due to inhibition of HDAC3 in SCs and not activity in other cell types, s we used a cell-type-specific strategy, in which we ablated HDAC3 in SCs of Hdac3-iKO mice using tamoxifen after nerve transection injury. HDAC3 expression was detected in denervated SCs marked by SOX10, and the number of HDAC3 + SCs increased substantially in the regenerating bridge tissues after nerve transection at 14 d.p.i. as compared to uninjured adult sciatic nerves (Fig. 4a) . We ablated HDAC3 Axon diameter (µm)
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Control by treating 8-week-old Hdac3-iKO and control mice with tamoxifen before and after sciatic nerve transection. This treatment efficiently removed HDAC3 specifically from the SCs of Hdac3-iKO mice (Fig. 4b) . At 14 d.p.i., a time point at which remyelination of the distal stump occurs 11, 28 , we observed an increase in differentiating EGR2 + SCs in the tissue bridge of Hdac3-iKO mice as compared to controls (Fig. 4c,d) , and the SC proliferation rate and number of immature SOX2 + SCs were reduced in Hdac3-iKO mice (Fig. 4e-h) . Hdac3-iKO mice had thicker myelin in transected sites than controls, as determined through EM analysis at 14 d.p.i. (Fig. 4i,j) , although the number of myelinating axons was comparable between the groups (Fig. 4k) . At 28 d.p.i., myelin sheaths were much thicker in the regenerating region of nerves in Hdac3-iKO mice than in controls (Fig. 4l) , with significantly lower g ratios than in control lesion sites or contralateral regions of intact nerves (Fig. 4m) . Tamoxifen treatment during this period did not alter myelin thickness in the uninjured nerves (Fig. 4m) .
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At 20 d.p.i., in vivo CMAP activity was barely detectable after electrical stimulation of injured nerves in control mice (Fig. 4n) . In contrast, we observed significantly greater CMAP signals in the injured nerves of Hdac3-iKO mice, as reflected by elevated conduction velocities and mean peak amplitudes (Fig. 4o,p) . Furthermore, Hdac3-iKO mice exhibited enhanced sensory function, as measured through pinprick stimulation (Fig. 4q) , and motor function, as determined through toespreading reflexes and a rotarod test (Fig. 4r,s) . These observations suggest that HDAC3 inhibition in denervated SCs accelerates SC maturation, enhances remyelination, and improves functional recovery.
HDAC3 negatively regulates NRG1-PI3K-AKT signaling to repress SC myelination The hypermyelinating phenotype observed in Hdac3-cKO mice resembles that of mice overexpressing NRG1 type III (ref. 35 ). As we did not detect significant differences in activation of the NRG1 receptors ErbB2 or ErbB3, as determined through the ratio of phosphorylated ErbB (p-ErbB) to ErbB, between the nerves of control and Hdac3-cKO mice at P13 (Supplementary Fig. 14) , we hypothesized that the effect of HDAC3 on SC myelination was due to activation of downstream pathways, such as PI3K-AKT and MAPK-ERK [36] [37] [38] . Indeed, we detected an increase in the levels of p-AKT, p-PI3K, and p-ERK in the nerves of Hdac3-cKO mice at P13 as compared to controls (Fig. 5a) . Similarly, inhibition of HDAC3 by PDA106 in purified rat SCs led to an elevation in p-AKT, p-PI3K, and p-ERK levels (Fig. 5b) . In addition, treatment with HDAC3 inhibitor or siHdac3 significantly increased the level of acetylated PTEN (Fig. 5c) , which resulted in a reduction of PTEN activity 39 , leading to activation of PI3K-AKT signaling.
Treatment of primary rat SCs with recombinant NRG1 type III for 1 h led to upregulation of HDAC3 expression (Fig. 5e) . This effect was occluded by the NRG1 signaling inhibitor gefitinib (Fig. 5f) , which blocks the signaling of the ErbB2 and ErbB3 receptors activated by NRG1 engagement 40 . Conversely, HDAC3 overexpression inhibited the phosphorylation of AKT and ERK that was induced by NRG1 in SCs (Fig. 5d) . In addition, treatment with NRG1 or the HDAC3 inhibitor PDA106 increased the p-ERK and p-AKT levels in SCs (Fig. 5g,h ), and combined treatment of NRG1 together with the HDAC3 inhibitor further enhanced p-ERK levels (Fig. 5g,h ). These observations suggest that NRG1 may induce expression of HDAC3, which in turn acts as a negative regulator of the NRG1 signaling pathway.
HDAC3 inhibits promyelinating programs and recruits p300 to activate a myelination-inhibitory network Although the Hdac3-deficient phenotype resembles that of NRG1-overexpressing mice, unique features, such as myelin outfoldings that are not induced by NRG1 overexpression, suggest that HDAC3 might regulate additional regulatory networks independent of NRG1 that block peripheral myelin overgrowth. To define the HDAC3-regulated genetic program that controls formation of myelin sheaths by SCs, we performed unbiased transcriptome profiling of control, Hdac3-cKO, and Hdac3-cKO Dhh sciatic nerves at P6, an active phase of SC differentiation. We applied weighted gene coexpression network analysis (WGCNA) to the data 41 to identify coexpressed gene modules with the most significant changes in both Hdac3-deficient models (Fig. 5i) . Our data indicate an upregulation of genes associated with myelination, lipid metabolic and biosynthetic processes, HIPPO signaling, and integrin signaling processes in Hdac3 mutants (Fig. 5j,k) all are processes known to be critical for SC myelination.
To further identify HDAC3 target genes with altered expression in Hdac3-cKO mutants, we performed chromatin immunoprecipitation and sequencing (ChIP-seq) analysis of HDAC3 genomic occupancy in SCs cultured under conditions fostering proliferation or differentiation. The intensity of HDAC3-binding sites was higher in differentiating SCs than in proliferating SCs (Supplementary Fig. 15a,b) . Recent studies indicate that, in the absence of the histone acetyltransferase (HAT) coactivator p300, HDAC3 occupancy represses target gene expression, while HDAC3 and p300, when both present, coordinately target enhancers marked by H3K27ac to promote expression of target genes, producing an overall increase in net HAT activity 42, 43 . HDAC3 targeted a set of genes different from those targeted by p300 in SCs (Fig. 5l) . These HDAC3-targeted genes with minimal p300 co-occupancy included the myelin-related genes Pmp22, Mpz, Mbp, Erbb2, and Gjb1 and promyelinating transcriptional regulatory genes such as Egr2, Zeb2, and Srebf1 (Supplementary Fig. 15c ). 
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In accordance, expression of these genes was increased in the sciatic nerves of Hdac3-cKO mice (Fig. 5i-k) , whereas overexpression of HDAC3 inhibited expression of these myelination-related genes (Supplementary Fig. 15d ). Furthermore, knockdown of HDAC3 in SCs led to an increased level of the activating histone mark H3K27ac on the enhancers of myelination-associated gene loci (Supplementary Fig. 16 ). These data reveal that HDAC3 and p300 targeted the same set of genes in differentiating SCs that coincide with enhancer elements marked by H3K27ac (Fig. 5l,m) . The gene loci bound by both HDAC3 and p300 were significantly enriched for genes encoding cell-growth-related factors and negative regulators of myelination (Fig. 5n) . These included Notch1, Hes5, Id2, Id4, Sox2, and Ngfr (p75; Fig. 5o) , as well as Pten and Dlg1, which are negative regulators of PI3K-AKT signaling (Fig. 5o) . Accordingly, expression of these genes was downregulated in the nerves of Hdac3-cKO mutants (Fig. 5p) . Similarly, at 14 d.p.i., expression of HDAC3-p300-targeted genes encoding negative regulators of myelination was upregulated in the regenerating tissue bridge, whereas myelination-associated genes and promyelination regulators were downregulated ( Supplementary  Fig. 17 ). Our data position coordination between HDAC3 and p300 at the apex of a gene regulatory network that controls both activation and inhibition of SC myelination via distinct mechanisms.
HIPPO effector TEAD4, an HDAC3-p300 target, is an inhibitor of SC myelin growth To identify new regulatory factors that inhibit myelin overgrowth, we next examined potential transcription factors regulated through the coordinated action of HDAC3 and p300. Tead4 was identified among the transcription factor gene loci co-occupied by HDAC3 and p300 (Supplementary Table 1) . The TEA-domain transcription factor 4 (Tead4) locus was enriched for the H3K27ac and H3K4me1 histone modifications, which mark active and poised enhancers 44 , respectively, on HDAC3-p300 co-targeted elements (Fig. 6a) , suggesting that HDAC3 and p300 co-occupancy may activate Tead4 expression. In contrast, the loci of TEAD family members Tead1-Tead3 were mainly targeted by HDAC3 but not p300 ( Supplementary  Fig. 18a ). Overexpression of HDAC3 and p300 in SCs promoted ; n = 3 independent experiments; one-way ANOVA with Tukey's multiple-comparisons test (Oct6: F (2, 6) = 46.18, P scr versus pHdac3 = 0.0002, P pHdac3 versus pHdac3 + siTead4 = 0.0005; Sox10: F (2, 6) = 48.37, P scr versus pHdac3 = 0.0025, P pHdac3 versus pHdac3 + siTead4 = 0.0001; Plp1: F (2, 6) = 58.43, P scr versus pHdac3 = 0.0005, P pHdac3 versus pHdac3 + siTead4 = 0.0001; Egr2: F (2, 6) = 34.41, P scr versus pHdac3 = 0.0016, P pHdac3 versus pHdac3 + siTead4 = 0.0004; Pmp22: F (2, 6) = 15.21, P scr versus pHdac3 = 0.0046, P pHdac3 versus pHdac3 + siTead4 = 0.0067; Mpz: F (2, 6) = 50.16, P scr versus pHdac3 = 0.0002, P pHdac3 versus pHdac3 + siTead4 = 0.0003; Mbp: F (2, 6) = 16.23, P scr versus pHdac3 = 0.0068, P pHdac3 versus pHdac3 + siTead4 = 0.0035). *P < 0.05, **P < 0.01, ***P < 0.001.
Tead4 expression to a significantly greater extent than either HDAC3 or p300 overexpression alone (Fig. 6b) . Conversely, Tead4 expression was significantly downregulated in siHdac3-treated SCs and the sciatic nerves of Hdac3-cKO mice (Supplementary Fig. 18b) .
Depletion of Tead4, but not Tead1, Tead2, or Tead3, significantly increased expression of myelination-associated genes Egr2, Pmp22, Mbp, and Mpz (Fig. 6c) while repressing expression of genes associated with inhibition of SC differentiation, such as Id2, Id4, and Sox2 (Fig. 6d) . The change in gene expression patterns upon depleting Tead4 correlated with increased myelination in the DRG-SC co-culture paradigm: the knockdown of Tead4 in SCs produced an increased number of myelin segments as compared to control-siRNA-treated SCs (Fig. 6e,f) , which was confirmed by an elevated level of the myelin proteins MBP and MPZ in SCs (Fig. 6g) . These results identify TEAD4 as a direct target of HDAC3-p300 regulation, which negatively regulates SC myelination.
To determine whether genetic ablation of Tead4 in the SC lineage produces hypermyelination phenotypes similar to Hdac3 deletion in vivo, we selectively ablated the expression of Tead4 in cells of SC lineage through breeding mice harboring a floxed Tead4 allele 45 (Fig. 6h-j) .Tead4 fl/fl ; Dhh-Cre +/− (referred to as Tead4-cKO) mice were born at the expected Mendelian frequency. At early postnatal stages, morphometric analysis did not reveal substantial alterations in expression of mature SC markers (Supplementary Fig. 19a-d) , whereas myelin thickness was slightly increased relative to controls (Supplementary Fig. 19e,f) . The myelin internodal length was not significantly altered in Tead4-cKO mice at P14 (Supplementary Fig. 20) . In contrast, in adult sciatic nerves, Tead4-cKO mutants developed profound hypermyelination and excessive myelin wraps, as shown by toluidine blue staining, ultrastructure, and g ratio analyses (Fig. 6k,l) , suggesting that sustained absence of TEAD4 leads to myelin overgrowth. Accordingly, we also observed an increase in expression of the major myelination-related genes in Tead4-cKO nerves through qRT-PCR (Fig. 6m) , whereas overexpression of TEAD4 in SCs inhibited expression of myelination-related genes (Fig. 6n) .
To test whether Tead4 loss is responsible for upregulation of myelin genes in Hdac3-deficient SCs, we inhibited Hdac3 expression using siRNA and then overexpressed Tead4. Silencing Hdac3 led to an 
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upregulation in expression of myelination-associated genes, whereas Tead4 overexpression repressed their expression (Fig. 6o) . Conversely, Hdac3 overexpression inhibited the expression of myelination-related genes and Tead4 inhibition partially restored their expression (Fig. 6p) .
DISCUSSION
Functional regeneration and recovery after nerve injury requires not only axonal regrowth but also remyelination of the regenerated axons 5, 25 . Despite the remarkable axonal regeneration capacity of peripheral nerves, myelin sheaths regenerated after injury are substantially thinner than myelin formed during development 4, 5 . Slow and compromised remyelination could contribute to the limited restoration of sensory and motor functions observed after proximal nerve injury in humans 29, 46 . In a small-molecule epigenetic screen, we found that pharmacological inhibitors of HDAC3 markedly elevated myelinogenic potential. Further, transient inhibition of HDAC3 activity robustly accelerated myelination and promoted functional recovery after peripheral nerve injury in mice. As peripheral nerve regeneration involves multiple processes, including axonal regeneration, SC migration, macrophage infiltration, and endothelial cell growth 5, 11, 47, 48 , HDAC3 inhibitors may also influence remyelination in a non-cell-autonomous manner, as pharmacological inhibition of HDAC3 enhanced axonal regrowth and blood vessel formation after nerve injury (Supplementary Fig. 21 ). Nonetheless, cell-type-specific genetic ablation demonstrated that Hdac3 loss in cells of SC lineage sufficed to increase SC maturation and myelinogenesis during nerve development and promoted denervated SC redifferentiation and myelination.
Inhibition of HDAC3 enhanced nerve conductivity after nerve injury not only in young adult mice but also in aging mice, suggesting that targeting HDAC3 may rejuvenate the age-related decline in functional recovery after nerve injury. As the axonal regeneration rate is comparable between young and aged mice (>20 months age) after nerve injury 49 , enhancement of SC myelination by HDAC3 inhibition likely contributes to conductivity restoration in aging mice, suggesting a potential therapeutic strategy for improving myelin repair in elderly individuals who often suffer from idiopathic peripheral neuropathy 50 .
Although nuclear export of HDAC5 in DRG neurons is critical for nerve regeneration 51 , we did not detect nuclear translocation of HDAC5 in SCs during nerve regeneration ( Supplementary  Fig. 22 ). HDAC3 exerts unique functions distinct from those of other class I HDACs, as inhibition of HDAC1/2 suppresses, rather than promotes, myelin sheath growth 23, 24 and blocks SC remyelination 52 , although transient pharmacological inhibition of HDAC1/2 increases the number of repair cells to promote axonal regrowth 17, 52 . This suggests distinct functions among individual HDAC family members in SC myelination and remyelination. In contrast to its later function as an inhibitor of SC maturation and myelinogenesis, HDAC3 promotes oligodendrocyte specification early in development 42 . Thus, HDAC3 may have a distinct role in development of myelinating cells in the central and peripheral nervous systems, although the potential HDAC3 functions in oligodendrocyte myelin growth and repair remain to be determined. Both the in vitro and in vivo pharmacological and genetic approaches described here provide evidence that HDAC3 acts in a cell-intrinsic manner on immature or premyelinating SCs to delimit myelin growth and regeneration.
Our results suggest that HDAC3 functions in a negative regulatory loop that restrains the activity of NRG1-PI3K-AKT signaling to ensure proper myelination and myelin growth. We found that HDAC3 antagonizes NRG1 signaling and its downstream myelinogenic program through blocking the activation of PI3K-AKT and ERK at the cellular level. It is possible that HDAC3, which can shuttle between the cytoplasm and nucleus 53 , may regulate the acetylation state of PTEN or PI3K-AKT to control kinase activity or turnover as in other contexts 54 . Alternatively, HDAC3 may indirectly regulate factors that inhibit NRG1-PI3K-AKT signaling. Our genomic occupancy and expression profiling analyses revealed that HDAC3, in coordination with p300, directly activates expression of Pten and Dlg1. In contrast to the loss of Pten-associated Dlg1, which leads to a transient increase of myelin thickness during development 55 , deletion of Hdac3 in SCs resulted in profound, sustained myelin sheath growth.
The HDAC3 expression pattern parallels that of NRG1 type III, for which the expression of genes increases during perinatal stages and then decreases in adulthood 56 . Downregulation of HDAC3 in adult nerves may correlate with a low level of NRG1; therefore, a minimal level of inhibition exerted by HDAC3 is sufficient to maintain myelin homeostasis in adult nerves. Alternatively, the low HDAC3 levels in adulthood are related to the previous formation of deacetylated chromatin or heterochromatin over myelination-related gene loci, obviating the need for histone deacetylation in adulthood. Thus, a developmental window of opportunity exists for modulating HDAC3 activity in immature or premyelinating SCs. Our observations suggest a potential role for a balance between NRG1-PI3K-AKT signaling and HDAC3 activity in fine-tuning myelin sheath thickness for optimal conduction velocity and nerve functions during development and recovery from injury.
Our genome-wide analysis of HDAC3 occupancy and transcriptome profiling revealed that HDAC3 inhibits the transcription of genes encoding promyelinating regulators in SCs. Inhibition of HDAC3 increased transcription of these genes and the deposition of activating H3K27ac marks on their enhancers and promoters. Thus, our observations suggest that HDAC3 exerts an inhibitory effect on SC myelination at least in part through epigenetic silencing of the promyelination program. Strikingly, we found that HDAC3 and p300 co-occupy the regulatory elements of genes associated with myelination inhibition, including Notch, Id2, Id4, Pten, and Dlg1. Coordination between HDAC3 and p300, which have similar temporal expression patterns (Supplementary Fig. 23 ), exerts net activating effects to activate a myelination-inhibitory network. Thus, HDAC3 may act as a dual-function switch via exerting an inhibitory effect through the epigenetic silencing of genes encoding proteins with promyelinating functions and through the recruitment of p300 to activate genes with products that inhibit SC myelination. The genome-wide HDAC3-p300 targeting analyses revealed the epigenetic landscape that underlies regulation of myelin growth; these will be an instructive reference for identifying regulatory networks that block peripheral myelin regrowth post-injury.
The genomic occupancy analyses further identified an HDAC3-p300 target, TEAD4, as a previously unrecognized inhibitor of SC myelin growth. In contrast to TEAD1, which cooperates with YAP-TAZ to activate myelination programs [14] [15] [16] , TEAD4 can also inhibit expression of myelination-associated genes in SCs, indicating a function divergent from those of other TEAD family members in SC myelination. Overexpressing YAP with TEAD4 led to net stimulation of Egr2 promoter activity in vitro 57 , whereas TEAD4 overexpression alone in the absence of YAP inhibited Egr2 expression, suggesting that there are context-dependent TEAD4 functions in gene regulation. Nonetheless, deletion of Tead4 in mice led to elevation of Egr2 and hypermyelination, consistent with the notion that TEAD4 functions as a default repressor and that YAP promotes tissue growth by relieving TEAD-mediated repression 58 .
The present study uncovered a previously unrecognized HDAC3-dependent pathway and epigenetic silencing that impact SC myelin growth and regeneration, providing insight into the epigenetic mechanisms underlying myelinopathy-associated diseases and nerve injury. Why functional recovery after trauma is slow and compromised remains unclear. Although it is possible that there is an insufficient supply of NRG1 after peripheral nerve injury, we found that the number of HDAC3-expressing SCs increased substantially after nerve injury. Thus, HDAC3 likely counters the activity of promyelinating signals, such as PI3K-AKT-ERK signaling. Inactivation of HDAC3 increased myelin thickness of SCs after nerve damage, suggesting that HDAC3 may limit full restoration of normal myelin thickness following injury.
Although the excessive hypermyelination seen with sustained Hdac3 ablation would not be a desirable endpoint, the potent activity of the druggable enzyme HDAC3 in the regulation of myelin sheath growth nevertheless highlights a therapeutic potential for time-or dose-delimited and controlled HDAC3 attenuation, which might allow SC re-entry into active myelinogenesis, overcoming the remyelination block in individuals with demyelinating neuropathies or nerve damage. In the mouse models described here, acceleration of myelin repair by measured and limited treatment with HDAC3 inhibitors facilitated timely recovery of conduction velocity as well as sensory and motor functions. Importantly, the myelin morphology in uninjured nerves was unaltered by treatment with HDAC3 inhibitors, indicating that transient HDAC3 inhibition is not detrimental to these nerves. Treatment with pharmacological HDAC3 inhibitors activated expression of myelination-associated genes in human SC-derived cell lines (Supplementary Fig. 24 ), suggesting that HDAC3 inhibition will promote the myelination program in human SCs. Given that HDAC inhibitors are generally well tolerated and have been clinically approved for treating certain cancers 59, 60 , pharmacological attenuation of HDAC3 activity and its regulatory circuits, including its downstream effector TEAD4, may represent a therapeutic avenue for enhancement of myelin repair in patients suffering from peripheral neuropathies and nerve trauma.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Mice. Mice homozygous for floxed alleles of Hdac3 (Hdac3 fl/fl ) 31 and Tead4 (Tead4 fl/fl ) 45 were crossed with mice carrying Dhh-Cre 33 or Cnp-Cre 32 to generate Hdac3-and Tead4-mutant mice, respectively. Mice with tamoxifeninducible Hdac3 knockout were generated through crossing Hdac3 fl/fl mice with Plp1-Cre ERT mice 34 , followed by tamoxifen injection. Mice of either sex were used in the study, and littermates were used as controls unless otherwise indicated. The mouse strains used in this study were generated and maintained on a mixed C57Bl/6; 129Sv background and were housed in a vivarium with a 12-h light-12-h dark cycle. All studies complied with all relevant animal use guidelines and ethical regulations. All animal use and study protocols were approved by the Institutional Animal Care and Use Committee at the Cincinnati Children′s Hospital Medical Center, Ohio, USA.
Rat primary Schwann cell culture. SCs from the sciatic nerves of newborn rats (1-2 d old) were isolated as described previously 12 . SCs were grown in DMEM with 10% FBS (Life Technologies), supplemented with 10 ng/ml neuregulin 1 (NRG1 type III; 396-HB-050, R&D Systems) and 5 µM forskolin (Sigma, F6886) plus l-glutamine and penicillin-streptomycin; this is hereafter denoted as SC proliferation medium. Cells between passages two and five were used in all experiments. >95% SC purity was achieved, as assessed by positive SOX10 and S100β immunoreactivity. To initiate differentiation, SCs were cultured in differentiation medium consisting of DMEM supplemented with 0.5% FBS and 1 mM dibutyl cyclic AMP (Sigma, D0627) along with l-glutamine and penicillin-streptomycin for 3 d. Human neurofibroma-derived SC lines SNF02.2 (ATCC, CRL-2885) and SNF96.2 (ATCC, CRL-2884) were propagated in DMEM supplemented with 10% FBS plus l-glutamine and penicillin-streptomycin. All tissue culture containers and coverslips were coated with 50 µg/ml poly(l-lysine) (Sigma, P7890) in PBS for at least 30 min at room temperature and then rinsed with distilled water.
Small-molecule compound screening. 96-well plates were coated with poly(l-lysine) (50 µg/ml) for 30 min at room temperature and then rinsed with distilled water and air dried. In each well, 5,000 primary SCs isolated from rat neonates were seeded and maintained in chemically defined medium consisting of DMEM with 10% FBS (Life Technologies) supplemented with 10 ng/ml NRG1 (R&D Systems, 396-HB-050) and 5 µM forskolin (Sigma, F6886) plus l-glutamine and penicillin-streptomycin for 2 d before screening. Each compound in the Epigenetics compound library (Cayman, 11076) was diluted to a final concentration of 5 µM in medium consisting of DMEM supplemented with 0.5% FBS, l-glutamine, and penicillin-streptomycin. SCs were treated with the diluted compounds for 8 h. These SCs were washed with PBS and then treated with the SingleShot Cell Lysis Kit (172-5080, Bio-Rad), following the manufacturer's instructions. The cell lysates from each well were collected for qRT-PCR using the iTaq Universal SYBR Green One-Step Kit (Bio-Rad, 172-5150), following the manufacturer's instructions. Each compound was tested in triplicate.
In vivo administration of HDAC3 inhibitors. The HDAC3 inhibitors RGFP966 (MedKoo, 510205; a selective HDAC3 inhibitor with an IC 50 of 80 nM; half-life, ~1 h) and PDA106 (MedKoo, 406720; preference toward HDAC3 inhibition with a K i of 14 nM; half-life, ~8 h) can pass through the blood-brain barrier and are benzamide-type HDAC3-selective inhibitors 21, 26, 27 . They were dissolved in DMSO (calculated to be 10% of the final volume) and diluted with 30% hydroxypropyl-β-cyclodextrin and 0.1 M acetate, pH 5.4. PDA106 and RGFP966 were administered at doses of 100 mg per kg body weight and 10 mg per kg body weight, respectively and separately, as previously described 21, 26 . Pups were given subcutaneous injections of drugs daily over the first week and i.p. injections every 2 d during the second week for a total of 3 d. Sciatic nerves were then collected and analyzed at the time points indicated in Figure 1d -k. For treatment of adult mice, drugs were i.p. injected daily after sciatic nerve transection injury in the first week and every 2 d after the first week for 3 d; they were analyzed at corresponding time points in Figure 2 . Administrations of the HDAC3 inhibitors were well tolerated, and no harmful side effects were observed in the mice throughout the entire period of experiments.
SC-DRG co-culture. DRG neurons were isolated from embryonic day (E) 16.5 rat spinal cords and plated as explants on collagen-coated coverslips. Cultures were maintained in serum-free neurobasal medium (NB medium; 2% B27 supplement, 2 mM l-glutamine, 0.4% glucose, and 50 ng/ml 2.5 S nerve growth factor (NGF) (Harlan, 005017)). Non-neuronal cells were removed via feeding the cultures with NB medium containing 5-fluorodeoxyuridine and uridine. SCs were isolated from sciatic nerves taken at P2 and expanded in SC proliferation medium. SC-DRG co-cultures were established through seeding purified DRG neuron cultures with 100,000 SCs in culture medium (MEM, 10% FBS, 2 mM l-glutamine, 0.4% glucose, and 50 ng/ml 2.5 S NGF). 3 d after SC plating, C medium was supplemented with 50 µg/ml ascorbic acid (Sigma, A0278) to initiate myelination. SC-DRG co-cultures were allowed to myelinate for 10 d, with fresh media provided every 2 d. To determine the extent of myelination in SC-DRG co-cultures, the total number of MBP + segments was counted in micrographs from 10-12 random fields per coverslip.
Tamoxifen induction of floxed allele deletion. Tamoxifen (Sigma, T5648) was dissolved to a stock concentration of 20 mg/ml in a vehicle of ethanol and sunflower seed oil (1:9 vol/vol). For perinatal tamoxifen injections, tamoxifen stock was injected i.p. at 2 mg/100 µl to lactating mice, thus administering tamoxifen to neonatal pups, beginning at P0. Tamoxifen was injected i.p. into pups after P5. Control mice were treated identically with tamoxifen. Sciatic nerves of pups were analyzed at the dates indicated in Figure 1g ,i by immunostaining and EM.
Sciatic nerve transection injury. Young or aging adult mice were under general anesthesia with injection of a mixture of ketamine (90 mg per kg body weight) and xylazine (10 mg per kg body weight). Right sciatic nerves were exposed and transected at midthigh level. Exposed left sciatic nerves were used as uncut controls. Mice were treated with HDAC3 inhibitors or tamoxifen to delete floxed Hdac3 alleles following injury. Nerves were collected at the time points indicated in Figures 2 and 4 following surgery and processed for immunohistochemistry or EM.
of the sciatic nerve, and the distance between the recording and stimulating electrodes was measured directly on the nerve. Peak CMAP amplitude and CMAP duration were calculated from each stimulation paradigm. The average of the stimulations of the sciatic nerve for each paradigm were obtained and then averaged across animals.
Statistical analyses. All analyses were done using GraphPad Prism 6.00 (San Diego, CA; http://www.graphpad.com/). Data are shown in dot plots or bar graphs as mean ± s.e.m. P < 0.05 is deemed statistically significant. Data distribution was assumed to be normal, but this was not formally tested. Statistical analysis was performed using two-tailed unpaired Student's t-tests between two samples and one-way ANOVA with Tukey's post hoc analysis for multiple comparisons or as indicated. Quantifications were performed from at least three experimental groups in a blinded fashion. The n value was defined as the number of experiments that were repeated independently with similar results. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those generally employed in the field. No randomization was used to collect all the data, but data were quantified with blinding. No animals or data points were excluded from analyses.
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. All high-throughput data mentioned in the paper are publicly available from GEO under accession GSE93161. All data that support the findings of this study are available from the corresponding author upon reasonable request. Uncropped images of blots can be found in Supplementary Figures 25-27 Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those generally employed in the field.
Data exclusions
Describe any data exclusions.
No samples or animals were excluded from the analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
Yes, the experimental findings were reliably reproduced, for representative data used for statistical analysis, the number of animals or experiments is described in corresponding figure legends.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
As reported in Methods and figure legends, mice were randomly assigned to each group to receive vehicle or drug treatment
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For cell-based experiments, EM, immunohistochemistry, the genotypes of cells/ animals were known before the conduction of experiments. For image analysis, cell and EM images were quantified in a blinded manner.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Eukaryotic cell lines
a. State the source of each eukaryotic cell line used. Human Schwann cell-derived cell lines SNF02.2 (ATCC CRL-2885) and SNF96.2 (ATCC CRL-2884) used in this study were purchased from ATCC. Cells were cultured under the same condition as reported in the literature b. Describe the method of cell line authentication used. All cell lines were authenticated by American Type Culture Collection (ATCC) Bioresource Center.
c. Report whether the cell lines were tested for mycoplasma contamination.
All cells lines were regularly tested and negative for mycoplasma contamination.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
As reported in Methods section of "Animals" for the information of animal species and strains. The mouse strains used in this study were generated and maintained on a mixed C57Bl/6;129Sv background. Both male and female mice were used for the present study. Ages of animals and animal-derived materials used in the study were reported in corresponding legends.
Fig1d-k, wed use P1 mice for drug treatment Fig2, we used 8 weeks old mice for sciatic nerve injury studies Fig3, we used P1, P6, P7, P12, P18 mice for electron microscopy analysis Fig4, we used 8 weeks old mice for sciatic nerve injury studies Fig5, we used P6 mice for RNA-seq analysis Fig6, we used P120 mice for western blot and electron microscopy analysis FigS2, S3, S5, S10, S11, S12, S13, S19, we used P7, P14, P18, P32, P94, P105 and P50 mice for electron microscopy analysis FigS4 and S7, we used 8 weeks old and 10 months old mice for Compound muscle action potential recording analysis FigS6, we used P7, P14, P28 and P60 mice for immunostaining and western blot. FigS8, S9, S11, S19 -S23 we used P7, P14 and 8 weeks old mice for immunostaining
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Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The study did not involve human research participants.
